Phathom Pharmaceuticals (NASDAQ: PHAT) Navigates Revenue Guidance Cut and Strong Q2 Results

• Analyst firm Needham lowered its price target for Phathom Pharmaceuticals (NASDAQ: PHAT) to $22 from $28, reflecting a cautious outlook on the biopharmaceutical company's stock performance.
• The company revised its full-year 2026 revenue guidance downwards by $20 million, signaling potential challenges in its market performance and investor expectations.
• Despite the lowered forecast, Phathom reported strong second-quarter 2026 financial results, including record net revenues of $74.3 million and improved operating profitability.

Phathom Pharmaceuticals (NASDAQ: PHAT) is a biopharmaceutical company focused on developing and selling treatments for gastrointestinal diseases. On July 30, 2026, analyst firm Needham lowered its price target for Phathom to $22 from $28. This new target was set when the company's stock was trading at $9.03 per share.

The negative outlook follows a significant cut in the company's full-year 2026 revenue guidance. Phathom revised its forecast to a range of $300 million to $325 million. This is a $20 million reduction from the previously stated range of $320 million to $345 million, which was reaffirmed during a February 2026 earnings call.

Following the guidance change, law firm Levi & Korsinsky issued an investigation notice, as highlighted by PR Newswire. The market reacted strongly to the news, with Phathom's stock price falling 22.42% in a single day. The stock's trading volume for the day exceeded 7.61 million shares, showing high investor activity.

Despite the lowered guidance, Phathom reported strong second-quarter 2026 results. As detailed by GlobeNewswire, the company announced record net revenues of $74.3 million. This figure represents an 88% increase compared to the same quarter in the previous year and a 27% rise from the first quarter of 2026.

The company also improved its financial efficiency. Phathom achieved operating profitability for the first time, excluding non-cash expenses like stock-based compensation. Cash operating expenses fell by 34% from the second quarter of 2025, and the company ended the period with a cash balance of $182.5 million.